These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16317287)

  • 41. Indicine N-oxide binds to tubulin at a distinct site and inhibits the assembly of microtubules: a mechanism for its cytotoxic activity.
    Appadurai P; Rathinasamy K
    Toxicol Lett; 2014 Feb; 225(1):66-77. PubMed ID: 24300171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization.
    Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M
    Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
    Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
    FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced anticancer effect of Combretastatin A-4 phosphate when combined with vincristine in the treatment of hepatocellular carcinoma.
    Aboubakr EM; Taye A; Aly OM; Gamal-Eldeen AM; El-Moselhy MA
    Biomed Pharmacother; 2017 May; 89():36-46. PubMed ID: 28214686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tubulin-interactive natural products as anticancer agents.
    Kingston DG
    J Nat Prod; 2009 Mar; 72(3):507-15. PubMed ID: 19125622
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
    Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents.
    Yamazaki Y; Sumikura M; Masuda Y; Hayashi Y; Yasui H; Kiso Y; Chinen T; Usui T; Yakushiji F; Potts B; Neuteboom S; Palladino M; Lloyd GK; Hayashi Y
    Bioorg Med Chem; 2012 Jul; 20(14):4279-89. PubMed ID: 22727370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
    Wang F; Yang Z; Liu Y; Ma L; Wu Y; He L; Shao M; Yu K; Wu W; Pu Y; Nie C; Chen L
    Bioorg Med Chem; 2015 Jul; 23(13):3337-50. PubMed ID: 25937236
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.
    Schobert R; Biersack B; Dietrich A; Effenberger K; Knauer S; Mueller T
    J Med Chem; 2010 Sep; 53(18):6595-602. PubMed ID: 20731355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microtubule-disrupting effects of gallium chloride in vitro.
    Perchellet EM; Ladesich JB; Collery P; Perchellet JP
    Anticancer Drugs; 1999 Jun; 10(5):477-88. PubMed ID: 10477168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring the size adaptability of the B ring binding zone of the colchicine site of tubulin with para-nitrogen substituted isocombretastatins.
    Jiménez C; Ellahioui Y; Álvarez R; Aramburu L; Riesco A; González M; Vicente A; Dahdouh A; Ibn Mansour A; Jiménez C; Martín D; Sarmiento RG; Medarde M; Caballero E; Peláez R
    Eur J Med Chem; 2015 Jul; 100():210-22. PubMed ID: 26092446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-microtubule 'plinabulin' chemical probe KPU-244-B3 labeled both alpha- and beta-tubulin.
    Yamazaki Y; Sumikura M; Hidaka K; Yasui H; Kiso Y; Yakushiji F; Hayashi Y
    Bioorg Med Chem; 2010 May; 18(9):3169-74. PubMed ID: 20395148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
    Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes.
    Lee HY; Chang CY; Lai MJ; Chuang HY; Kuo CC; Chang CY; Chang JY; Liou JP
    Bioorg Med Chem; 2015 Aug; 23(15):4230-4236. PubMed ID: 26160020
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
    Kim S; Peshkin L; Mitchison TJ
    PLoS One; 2012; 7(7):e40177. PubMed ID: 22848372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes.
    Majcher U; Urbaniak A; Maj E; Moshari M; Delgado M; Wietrzyk J; Bartl F; Chambers TC; Tuszynski JA; Huczyński A
    Bioorg Chem; 2018 Dec; 81():553-566. PubMed ID: 30248507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
    Greene LM; Nathwani SM; Bright SA; Fayne D; Croke A; Gagliardi M; McElligott AM; O'Connor L; Carr M; Keely NO; O'Boyle NM; Carroll P; Sarkadi B; Conneally E; Lloyd DG; Lawler M; Meegan MJ; Zisterer DM
    J Pharmacol Exp Ther; 2010 Nov; 335(2):302-13. PubMed ID: 20699436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
    Ji YT; Liu YN; Liu ZP
    Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
    Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
    Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.